With CEO search, PhI­II study un­der­way, Ful­crum Ther­a­peu­tics rais­es $125M from stock of­fer­ing

Who­ev­er be­comes the next CEO of Ful­crum Ther­a­peu­tics will have $125 mil­lion more to work with.

The com­pa­ny is sell­ing off 9.6 mil­lion shares of its com­mon stock at a price of $13 per share in a pub­lic of­fer­ing, com­plete with a 30-day op­tion for the un­der­writ­ers to pur­chase up to 1.4 mil­lion shares with a clos­ing date of Jan. 23, the com­pa­ny an­nounced Tues­day.

The an­nounce­ment of the pub­lic of­fer­ing comes af­ter a busy year for the com­pa­ny, in­clud­ing fast track des­ig­na­tion from the FDA and the com­ple­tion of sev­er­al clin­i­cal tri­als and en­roll­ment pe­ri­ods for more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER